PSA is a serine protease that functions to break down and liquefy semen clots that form after ejaculation. PSA is a product of the prostatic epithelium and is normally secreted in semen. The PSA test is usually used to diagnose prostate cancer, but it has a number of limitations. PSA can be increased in conditions of prostate gland disease, both benign and malignant. This is because PSA is specific for certain organs but is not specific only for cancer. This study aims to determine the profile of PSA in prostate disease at Hasan Sadikin Bandung General Hospital. This study involved 375 patients and is a retrospective descriptive study by taking medical record data from patients with prostate disease who went to the Urology Polyclinic during the period January-December 2019. The results of the study were processed with descriptive statistics and then presented in the form of tables and explanatory narratives. Based on the results of the study, patients with Benign Prostatic Hyperplasia (BPH) had a mean PSA value of 8.05 + 32.31 ng/ml, prostate cancer patients had a mean PSA value of 188.75 + 344.67 ng/ml and in prostatitis patients had the average PSA value is 2.1 + 0.76. There are differences in PSA values in patients with BPH, prostate carcinoma, and prostatitis.